TAGCyx is a bio-pharmaceutical company that utilizes innovative new artificial base pair technologies to create DNA aptamers through their drug discovery platform. These aptamers represent the next generation of therapeutics following antibodies, and TAGCyx aims to contribute to society by delivering highly effective and safe medicines to a larger population at an affordable cost. The company specializes in the development of high-performance nucleic acid drugs with exceptional affinity and specificity for target molecules, thanks to their proprietary nucleic acid basic technology.

Their research and development products include treatments for conditions such as interstitial cystitis, Sjögren's syndrome, alopecia areata, thrombocytopenic purpura, and preeclampsia. With their focus on innovation and cutting-edge technology, TAGCyx is dedicated to advancing healthcare and improving the lives of individuals worldwide